Table 3.
Fucoidan | Model | Adminstration | Observation | Reference |
---|---|---|---|---|
Fucus vesiculosis Macrocystis pyrifera Laminaria japonica |
Human clinical | Oral daily 100 mg or 1000 mg for three months | No toxicity Up to 52% reduction in symptoms |
Myers 2010 [27] |
Fucus fucoidan (Sigma) | Mouse with surgical destabilization of the medial meniscus | 20 mg/kg intraperitoneal injection | Fucoidan suppressed cellular infiltration of joint and suppress post-operative (3 days), but not late (16 weeks) pain | Mcnamee 2010 [70] |
Fucus fucoidan (Sigma) | Wistar rats with carrageenan induced local inflammation in the footpad | 20 mg/kg intravenously | Fucoidan inhibits mechanical hypernociception and neutrophil migration | Cunha 2008 [69] |
Undaria pinnatifida fucoidan | Collagen induced arthritis in mice | 100 kDa, 3.5 kDa and 1 kDa fractions orally administered daily 300 mg/kg to 49 days | 1 kDa fraction effectively inhibited whereas 100 kDa exacerbated disease | Park 2010 [41] |